FDA review is pending for cemdisiran submission from Regeneron Pharmaceuticals.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA review is pending for cemdisiran submission from Regeneron Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Experimental therapies require approval from the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireRegeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints,